Lexeo Therapeutics LXEO 深 滬
等待開盤 09-24 09:30:00 美东时间
3.52
-0.550
-13.51%
華盛通- 最 高4.09
- 今 開4.07
- 成交量 242.54万股
- 最 低 3.455
- 昨 收 4.07
- 總市值 2.89亿
- 52周最高 10.99
- 市盈率 靜 --
- 換手率 2.96%
- 52周最低 3.455
- 委 比 -67.17%
- 總股本 8204.63万
- 歷史最高 22.33
- 量 比 1.52
- 振 幅 15.60%
- 歷史最低 1.45
- 每 手 1
- 風險率 1.90%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Ericsson, Lexeo Therapeutics And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
U.S. stock futures were mixed this morning, with the Dow futures gaining around 0.2% on Tuesday. Shares of Telefonaktiebolaget LM Ericsson – ADR (NASDAQ:ERIC) fell sharply in pre-market trading. Morgan Stanley analyst Terrance Tsul downgraded the stock from Equal-Weight to Underweight and slashed th...
09-22 20:01
Lexeo Therapeutics expands FA pipeline with Mantle acquisition
Lexeo Therapeutics, Inc. ( ($LXEO) ) has issued an announcement. On September 1...
09-22 19:29
Lexeo Therapeutics Enters Into Agreement to Acquire Mantle Therapeutics and Announces Multiple New Strategic Collaborations to Expand Leadership in Friedreich Ataxia
Lexeo Therapeutics announced the acquisition of Mantle Therapeutics and three new collaborations to expand its Friedreich ataxia (FA) platform, adding therapies to increase or replace frataxin in the brain. The acquisition includes four programs targeting frataxin restoration, with LX2006 remaining the top priority. Lexeo also plans to explore sequential dosing and cerebellar targeting through collaborations. The company expects to advance one ac...
09-22 11:00
Lexeo Therapeutics to Participate in Upcoming Investor Conferences in September
Lexeo Therapeutics, Inc. announced that its management will participate in two investor conferences in September 2026: the Cantor Global Healthcare Conference on September 9 and the Baird Global Healthcare Conference on September 15. Both events will be live webcast and available for replay on the company's website. Lexeo, a clinical-stage genetic medicine company focused on treating cardiovascular diseases, is advancing therapeutic candidates ta...
09-02 11:00
Lexeo Therapeutics Q2 EPS $(0.30) Misses $(0.28) Estimate
Lexeo Therapeutics (NASDAQ:LXEO) reported quarterly losses of $(0.30) per share which missed the analyst consensus estimate of $(0.28) by 7.14 percent. This is a 50 percent increase over losses of $(0.60) per share from the same period last year.
08-12 19:08
Lexeo Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for LX2020 for the Treatment of PKP2 Arrhythmogenic Cardiomyopathy
Lexeo Therapeutics announced that the FDA has granted RMAT designation to LX2020, its gene therapy for PKP2-associated arrhythmogenic cardiomyopathy (PKP2-ACM), based on interim clinical data from the ongoing HEROIC-PKP2 trial. LX2020 now holds RMAT, Orphan Drug, and Fast Track designations. The designation highlights the potential of LX2020 to address the underlying genetic cause of PKP2-ACM, a serious cardiovascular disease with no approved dis...
08-05 11:00
Fermi, Delta Air Lines And Other Big Stocks Moving Lower In Friday’s Pre-Market Session
U.S. stock futures were mixed this morning, with the Dow futures gaining around 100 points on Friday. Shares of Fermi Inc (NASDAQ:FRMI) fell sharply in pre-market trading after the company priced an upsized $375 million convertible senior notes offering with capped call transactions designed to redu...
07-10 20:03
美股大行评级 | 潜在涨幅135.66%！Ocular Therapeutix获Chardan Capital升目标价至23美元，维持"买入"评级
今日重点评级关注：Chardan Capital：维持Ocular Therapeutix"买入"评级，目标价从21美元升至23美元；Guggenheim：维持Amylyx Pharmaceuticals"买入"评级，目标价从30美元升至40美元
06-26 17:42
JP Morgan Maintains Overweight on Lexeo Therapeutics, Lowers Price Target to $9
JP Morgan analyst Tessa Romero maintains Lexeo Therapeutics (NASDAQ:LXEO) with a Overweight and lowers the price target from $12 to $9.
06-25 22:54
Lexeo Therapeutics Reports Data For LX2006 Gene Therapy In Friedreich Ataxia, Pivotal SUNRISE-FA 2 Study On Track For 2026 Launch, Publishid In The JAMA Cardiology
Published findings in JAMA Cardiology demonstrate LX2006 generally well tolerated, with early signs of efficacy in Phase I/II studies SUNRISE-FA 2 pivotal study for LX2006 on track to initiate in Q2 2026 with topline data expected in 2H 2027 NEW YORK, June 17, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeu...
06-18 04:04
